Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Blood

• Publication date

  2006-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2005-11-4385PMID 16434487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

  2005influential reference
• Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.

  2004cited by this paper
• High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

  2004cited by this paper
• Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

  2004cited by this paper
• Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

  2004cited by this paper
• Molecular mechanisms of amyloidosis.

  2003cited by this paper
• Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure.

  2003cited by this paper
• Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

  2003cited by this paper
• Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis

  2003cited by this paper
• Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals.

  2003cited by this paper
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

  2002cited by this paper
• Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

  2002cited by this paper
• Autologous stem cell transplantation for primary systemic amyloidosis.

  2002cited by this paper
• Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis

  2002cited by this paper
• Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains

  2002cited by this paper
• The Pavia Approach to Clinical Protein Analysis

  2001cited by this paper
• Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

  2001cited by this paper
• Diagnostic potential of cardiac natriuretic peptides in dialysis patients.

  2001cited by this paper
• The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.

  1998cited by this paper
• Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

  1995cited by this paper

• Improvement in global longitudinal strain following plasma cell-directed therapy is associated with long-term survival among patients with AL amyloidosis

  2025cites this paper
• The evolving spectrum of kidney amyloidosis: advances in diagnosis, typing and treatment.

  2025cites this paper
• A 2D-STI echocardiographic diagnostic model established for cardiac amyloidosis complicated with multiple myeloma.

  2025cites this paper
• Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response

  2025cites this paper
• A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils

  2025cites this paper
• Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells

  2025cites this paper
• A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis

  2025cites this paper
• In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls, and potential

  2025cites this paper
• Pulmonary amyloidosis: a case report

  2025cites this paper
• Piecing together the intricate puzzle of organ recovery in AL amyloidosis

  2024cites this paper
• Early experience with daratumumab-containing regimens in patients with light-chain cardiac amyloidosis.

  2024cites this paper
• Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response

  2024cites this paper
• The Pathophysiological and Therapeutic Implications of Cardiac Light-Chain Amyloidosis Compared With Transthyretin Amyloidosis.

  2024cites this paper
• Cardio-Hepatic Interaction in Cardiac Amyloidosis

  2024cites this paper
• Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?

  2024cites this paper
• Associations of Patients with Pericardial Effusion Secondary to Light-Chain or Transthyretin Amyloidosis- A Systematic Review

  2024cites this paper
• PRIMARY SYSTEMIC AMYLOIDOSIS: A BRIEF OVERVIEW.

  2024cites this paper
• Successes in translation

  2024cites this paper
• Mechanistic insights into the aggregation pathway of the patient-derived immunoglobulin light chain variable domain protein FOR005

  2023cites this paper
• Amyloidogenic light chains impair plasma cell survival

  2023cites this paper
• Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC)

  2023cites this paper
• Vector autoregression: Useful in rare diseases?—Predicting organ response patterns in a rare case of secondary AA amyloidosis

  2023cites this paper
• Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology

  2023cites this paper
• Individualized Approach to Management of Light Chain Amyloidosis.

  2023cites this paper
• Epidemiology and clinical outcomes of light‐chain amyloidosis in Sweden: A nationwide population‐based study

  2023cites this paper
• Perioperative implications of amyloidosis and amyloid cardiomyopathy: A review for anesthesiologists.

  2023cites this paper
• Pulmonary manifestations of amyloidosis.

  2023cites this paper
• Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis

  2023cites this paper
• Amylose AL : focus sur l’atteinte rénale et les aspects hématologiques

  2023cites this paper
• Understanding and Overcoming Biochemical Diversity in AL Amyloidosis

  2023cites this paper
• Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation

  2023cites this paper
• Diagnosis and Treatment of AL Amyloidosis

  2023cites this paper
• The Cryo-EM structure of renal amyloid fibril suggests structurally homogeneous multiorgan aggregation in AL amyloidosis.

  2023cites this paper
• Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis

  2022cites this paper
• Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group

  2022cites this paper
• Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist

  2022cites this paper
• Cu(II) Binding Increases the Soluble Toxicity of Amyloidogenic Light Chains

  2022cites this paper
• Mechanisms of Organ Damage and Novel Treatment Targets in AL Amyloidosis

  2022cites this paper
• Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis

  2022cites this paper
• A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea

  2022cites this paper
• Understanding AL amyloidosis with a little help from in vivo models

  2022cites this paper
• Miocardiopatía restrictiva por amiloidosis de cadenas ligeras. Mejoría post CYBORD.

  2022cites this paper
• Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis.

  2022cites this paper
• Advances in the treatment of light chain amyloidosis

  2022cites this paper
• Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

  2022cites this paper
• TASK FORCE OF THE WORKING GROUP ON MYOCARDIAL AND PERICARDIAL DISEASE ON: A position statement of the ESC Working on

  2022cites this paper
• Emerging from the Darkness. Sudden Cardiac Death in Cardiac Amyloidosis

  2022cites this paper
• Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.

  2022cites this paper
• Learning from Patients: The Interplay between Clinical and Laboratory Research in AL Amyloidosis

  2021cites this paper
• Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis.

  2021cites this paper
• Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.

  2021cites this paper
• Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management

  2021cites this paper
• Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis

  2021cites this paper
• Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis

  2021cites this paper
• Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics

  2021cites this paper
• Immunoglobulin light chain amyloidosis

  2021cites this paper
• First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

  2021cites this paper
• The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis

  2021cites this paper
• Radionuclide Imaging of Cardiac Amyloidosis.

  2021cites this paper
• Cardiac Amyloidosis – An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction – Updated Diagnosis and Treatment Options

  2021cites this paper
• Use of biomarkers to diagnose and manage cardiac amyloidosis

  2021cites this paper
• Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM

  2021cites this paper
• Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses

  2020cites this paper
• Utility of Biomarkers in Cardiac Amyloidosis.

  2020cites this paper
• Management of AL amyloidosis in 2020.

  2020cites this paper
• Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

  2020cites this paper
• MONOCLONAL GAMMOPATHIES OF DETERMINED SIGNIFICANCE Management of AL amyloidosis in 2020

  2020cites this paper
• Solid Organ Transplantation in Amyloidosis

  2020cites this paper
• Diagnosis and management of systemic light chain AL amyloidosis.

  2020cites this paper
• The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis

  2020cites this paper
• Prognosis and Staging of AL Amyloidosis

  2020cites this paper
• Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside

  2020cites this paper
• Systemic light chain amyloidosis

  2020cites this paper
• Cardiac amyloidosis-an underdiagnosed cause of heart failure in the elderly

  2020cites this paper
• Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement.

  2020cites this paper
• Management of AL amyloidosis in 2020.

  2020cites this paper
• Amyloidosis of the respiratory system: 16 patients with amyloidosis initially diagnosed ante mortem by pulmonologists

  2020cites this paper
• Cardiac Amyloidosis: A Case Series from India.

  2019cites this paper
• New Insights Into a Multifaceted Disease.

  2019cites this paper
• Inherent biophysical properties modulate the toxicity of soluble amyloidogenic light chains.

  2019cites this paper
• Predicting survival in light chain amyloidosis

  2019cites this paper
• Amyloidosis in Heart Failure

  2019cites this paper
• Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.

  2019cites this paper
• Grading cardiac response in AL amyloidosis: implications for relapse and survival

  2019cites this paper
• Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration.

  2019cites this paper
• Cardiac amyloidosis—an underdiagnosed cause of heart failure in the elderly

  2019cites this paper
• Use of novel therapies in the treatment of light chain amyloidosis.

  2019cites this paper
• EXPLORING THE MOLECULAR AND BIOPHYSICAL MECHANISMS OF PROTEOTOXIC IMMUNOGLOBULIN LIGHT CHAINS IN AL AMYLOIDOSIS

  2019cites this paper
• Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients.

  2018cites this paper
• Amiloidosis pulmonar alveolo septal calcificada como manifestación inicial de mieloma múltiple

  2018cites this paper
• Primary cardiac amyloidosis.

  2018cites this paper
• Animal models of monoclonal immunoglobulin-related renal diseases

  2018cites this paper
• Light Chain Amyloidosis

  2018cites this paper
• Calcified Alveolar Septal Pulmonary Amyloidosis as an Initial Manifestation of Multiple Myeloma

  2018cites this paper
• Wikilite > 28-AL amyloidosis

  2018cites this paper
• Trifascicular block as primary presentation of the cardiac amyloidosis; A rare case report

  2018cites this paper
• Familial Cardiac Amyloidoses

  2018cites this paper
• Calcified Alveolar Septal Pulmonary Amyloidosis as an Initial Manifestation of Multiple Myeloma.

  2018cites this paper
• AL Cardiac Amyloidosis: Classification, Diagnosis, and Treatment

  2018cites this paper
• Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis

  2017cites this paper